Welcome to our dedicated page for Monogram Orthopaedics news (Ticker: MGRM), a resource for investors and traders seeking the latest updates and insights on Monogram Orthopaedics stock.
Monogram Technologies Inc. (formerly Nasdaq: MGRM) generated news as an AI-driven orthopedic robotics company focused on total knee arthroplasty and patient-optimized implants. Company press releases and SEC filings highlight developments in robotic-assisted surgery, regulatory milestones, clinical trials and corporate transactions, including its acquisition by Zimmer Biomet.
News coverage for Monogram has emphasized progress with its mBôs TKA System and mPress implants. The company announced FDA 510(k) clearance for the Monogram mBôs TKA System, allowing it to market the device subject to the Federal Food, Drug, and Cosmetic Act. Monogram also reported FDA clearance for its mPress implants and described plans to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables and other instrumentation necessary for reconstructive joint replacement procedures.
Another key stream of news involves Monogram’s clinical and international activities. The company disclosed that India’s Central Drugs Standard Control Organization approved import of the mBôs TKA system for a 102-patient, multi-center clinical investigation in collaboration with Shalby Limited, described as one of the world’s largest orthopedic hospital groups. In July 2025, Monogram announced what it called the world’s first fully autonomous saw-based robotic knee replacement surgery on a live patient, performed at Krishna Shalby Hospital in Ahmedabad, India, as part of this trial.
Corporate and capital markets updates have also been central to MGRM-related news. Monogram reported financing-related actions such as the mandatory conversion of its 8.00% Series D Convertible Cumulative Preferred Stock after a specified trading condition was met. In July 2025, Zimmer Biomet and Monogram jointly announced a definitive agreement for Zimmer Biomet to acquire all outstanding shares of Monogram, with additional details provided in subsequent SEC filings and communications to shareholders. Later, an October 2025 Form 8-K confirmed completion of the merger, after which Monogram became a wholly owned subsidiary of Zimmer Biomet and its common stock was delisted from Nasdaq.
Investors and observers reviewing the MGRM news feed can therefore expect historical updates on robotic knee surgery milestones, regulatory clearances, international clinical trials, preferred stock actions, and the sequence of events leading to the Zimmer Biomet acquisition and delisting of the MGRM ticker.
Zimmer Biomet (NYSE:ZBH) reported strong Q2 2025 financial results with net sales of $2.077 billion, up 7.0% year-over-year. The company achieved diluted EPS of $0.77 and adjusted EPS of $2.07, representing a 3.0% increase.
Key highlights include robust growth in U.S. Hips (5.2%) and Knees portfolios, along with significant S.E.T. business growth of 17.3%. The company announced a strategic acquisition of Monogram Technologies to expand its robotics capabilities and formed a partnership with Getinge for Operating Room products distribution.
Zimmer Biomet raised its 2025 guidance, now expecting revenue growth of 6.7-7.7% (reported) and adjusted EPS of $8.10-$8.30, up from previous guidance of $7.90-$8.10.
Monogram Technologies (NASDAQ: MGRM) has achieved a historic milestone by completing the world's first fully autonomous saw-based robotic knee replacement surgery on a live patient. The groundbreaking procedure was performed on July 26, 2025, at Krishna Shalby Hospital in Ahmedabad, India, using Monogram's mBôs TKA System.
The surgery is part of a 102-patient multi-center clinical trial in India, approved by CDSCO, evaluating the system's safety and effectiveness. The procedure utilized the Consensus CKS implant, which is substantially equivalent to Monogram's mPress implants. This achievement follows the recent FDA 510(k) clearance for Monogram's semi-autonomous TKA System and comes amid Zimmer Biomet's (NYSE: ZBH) pending acquisition of Monogram.
Zimmer Biomet (NYSE: ZBH) has announced a definitive agreement to acquire Monogram Technologies (NASDAQ: MGRM) for an upfront payment of $4.04 per share, representing an equity value of approximately $177 million. The deal includes a CVR worth up to $12.37 per share tied to development milestones through 2030.
The acquisition will expand Zimmer Biomet's ROSA® Robotics platform with Monogram's semi- and fully autonomous robotic technologies. Monogram's FDA-cleared CT-based, semi-autonomous AI-navigated total knee arthroplasty technology is expected to be commercialized with Zimmer Biomet implants in early 2027. The deal positions Zimmer Biomet to potentially become the first company to offer fully autonomous surgical robots in orthopedics.
The transaction is expected to be neutral to adjusted EPS in 2025-2027 and accretive thereafter, with revenue growth contribution beginning in 2027. The deal is anticipated to close later in 2025, subject to regulatory and shareholder approvals.
Monogram Technologies (NASDAQ:MGRM) has announced the mandatory conversion of all outstanding shares of its 8.00% Series D Convertible Cumulative Preferred Stock. The conversion was triggered after the company's common stock price closed at or above $2.8125 per share for 10 consecutive trading days through July 7, 2025.
The Series D Preferred Stock was originally issued during an offering that closed on October 1, 2024, where units consisted of one preferred share and one common stock purchase warrant. The mandatory conversion will become effective on July 14, 2025.
Monogram Technologies (NASDAQ: MGRM) reported its Q1 2025 financial results and achieved significant milestones. The company received FDA 510(k) clearance for its mBôs™ Total Knee Arthroplasty (TKA) System and obtained regulatory approval from India's CDSCO to initiate a 102-patient clinical trial with Shalby Limited. The trial will demonstrate fully autonomous, hands-free, saw-based robotic total knee surgeries on live patients, expected to begin within 90 business days.
Financial highlights for Q1 2025 include: R&D expenses decreased 6% to $2.3M, marketing expenses dropped 63% to $44,000, and G&A expenses were $1.0M. The company reported a net loss of $3.2M, improving from $3.5M in Q1 2024. Cash and equivalents stood at $13.3M as of March 31, 2025.
Monogram Technologies (NASDAQ:MGRM), an AI-driven robotics company focused on orthopedic surgery, has scheduled its Q1 2025 earnings conference call for May 14, 2025, at 4:30 p.m. Eastern Time. CEO Ben Sexson and CFO Noel Knape will host the webcast, which will cover financial results for the quarter ended March 31, 2025, regulatory updates, and key milestones.
The call will include discussions on their recent FDA 510(k) Clearance for the Monogram mBôs TKA System and approval to initiate clinical trials in India. A detailed press release will be issued before the call, and a presentation will be available through the company's investor relations website.
[]Monogram Technologies has received regulatory approval from India's CDSCO to begin clinical trials of its mBȏs TKA System for knee replacement surgery. The company will conduct a 102-patient, multi-center study in partnership with Shalby Hospitals, one of the world's largest orthopedic hospital groups.
The trial will evaluate the safety and effectiveness of the Monogram TKA System with the Consensus CKS implant. Patient enrollment is expected to begin shortly, with first surgeries anticipated within 90 business days. The company has already delivered training systems and hosted investigator meetings in Ahmedabad, India.
The clinical investigation is supported by Reliance Life Sciences, which manages regulatory submissions in India. Dr. Vikram I. Shah, Shalby Hospitals' Founder and Chairman, recently featured in TIME Magazine Asia Edition, endorsed the mBȏs System as the most advanced robotic technology in orthopedic medicine.
Monogram Technologies has received regulatory approval from India's CDSCO to import its mBôs TKA System for a clinical trial. The study, conducted with Shalby Hospitals, will evaluate the safety and effectiveness of their robotic knee replacement system across multiple centers in India.
Key highlights:
- 102 total knee replacement procedures planned
- Three-month clinical follow-up period
- First surgeries expected within 90 business days
- Training version already delivered in January
- Full-time employees will be deployed to India for support
The partnership with Shalby, one of the world's largest orthopedic hospital groups, and support from Reliance Life Sciences marks a significant step in advancing orthopedic innovation globally. The trial aims to demonstrate the system's performance in real surgical settings, including technically demanding cases, as Monogram progresses toward commercial launch.
Monogram Technologies (NASDAQ:MGRM), an AI-driven robotics company specializing in orthopedic surgery, has announced a strategic partnership with Urvin to launch an exclusive, verified shareholder communication platform.
The new platform creates a private message board exclusively for verified, active Monogram shareholders, enabling direct communication between investors while providing the company with an efficient channel for important updates. Access to the community is contingent on maintaining active share ownership, ensuring discussions remain focused among those with current investments.
Shareholders can join the platform by registering at urvin.finance using their transfer agent-registered email address and accessing the Verified Shareholder Communities section. This initiative aims to enhance shareholder engagement and streamline corporate communications, particularly during key company events.
Monogram Technologies (NASDAQ:MGRM) has received FDA 510(k) clearance for its Monogram mBôs TKA System, a robotic-assisted technology for total knee arthroplasty. The system is designed to deliver enhanced safety, efficiency, and accuracy in knee replacement procedures.
The clearance allows Monogram to market the device under the Federal Food, Drug, and Cosmetic Act's provisions. The company plans to integrate recent upgrades to the cutting system and other enhancements to strengthen its market competitiveness.
Monogram's commercialization strategy includes:
- Initial placements with key surgeon KOLs in strategic locations
- System demonstrations in real-world surgical settings
- Potential international expansion, including clinical trials in India with Shalby
- Development of additional clinical applications to establish it as a multi-application platform
FAQ
What is the current stock price of Monogram Orthopaedics (MGRM)?
What is the market cap of Monogram Orthopaedics (MGRM)?
